Technology Overview

Innovative Innovations

iNtRON's Platform Technology

iNtRON's platform technology consists of PHAGERIARUS® technology to develop “Immune & Immunotherapeutics” and itLysin® to develop “Anti-Infectious Diseases Drugs”, PHAGERIA®, PHAGERUS®, and im-MucoDr® mRNA-related technologies.

We have expanded our Target Disease Area through long experience and verification. Our platform technologies can be divided into (1) “BC” (Before anti-Cancer Immunotherapeutics, Before Concept) Era before the development of “Immune & Immunotherapeutics” and (2) “AD” (After Anti-Infectious Disease Drugs, After New Definition/Doctrine) Era.

The core of PHAGERIARUS® is to view bacteriophages as foreign substances that invade the human body, such as bacteria and viruses. In other words, it presents a new perspective on the immune system in the human body in relation between bacteria, viruses, and bacteriophages. We are developing PHAGERIARUS® as a core technology for developing a number of immunotherapeutics, including immuno-cancer drugs, through the paradigm shift of existing immunology.

Our first development goal is immunotherapy for cancer. Immune regulators will be developed using our PHAGERIARUS® technology, resulting in immunotherapeutics. Furthermore, we will develop new drugs to treat various immune diseases, such as Alzheimer's, Parkinson's, and Diabetes using immune system regulators.

Our Technologies

iNtRON
Technologies
After and-infectious Disease Drug
After Definition/Doctrine
AD Era
Before anti-Cancer Immunotherapeutics
Before Concept
BC Era
PHAGERIARUS®

Development of a number of immunotherapeutics through the development of new BΦPTA or Immune Regulators based on ViP-Cycle

PHAGERUS®

Development of treatments and vaccines targeting viral infectious diseases based on the similarity between bacteriophages and viruses

PHAGERIA®

Development of new biopharmaceuticals targeting CRC, PD, and AD by regulating the gut microbiome with bacteriophages that respond to bacteria

itLysin®

Development of new biopharmaceuticals targeting bacterial infections including antibiotic-resistant bacteria by suing engineered endolysin based on itLysin® technology